Marseille, France, May 30, 2024: ImCheck Therapeutics announced today that updated data from its ongoing Phase I/II study EVICTION will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago. The poster will provide new data from the study assessing ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, in combination with checkpoint inhibitor (CPI) pembrolizumab. The results, specifically in patients with CPI-refractory melanoma, support the therapeutic potential of the ICT01‒pembrolizumab combination. To know more